Anti-Diabetes Drugs - Mexico

Mexico

In Mexico, the revenue in the Anti-Diabetes Drugs market is estimated to reach US$0.63bn by 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2028) of 4.80%, leading to a market volume of US$0.76bn by 2028.
When compared globally, United States is anticipated to generate the highest revenue of US$35,630.00m in 2024.
Mexico is experiencing a growing demand for innovative anti-diabetes drugs due to the high prevalence of diabetes in the country.

Key regions: India, Canada, Australia, France, Italy

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Mexico has been steadily growing in recent years.

Customer preferences: Mexican consumers are becoming increasingly health-conscious and aware of the risks associated with diabetes. As a result, there has been a growing demand for anti-diabetes drugs in the country. Additionally, the aging population in Mexico is also contributing to the growth of the market.

Trends in the market: One of the key trends in the Anti-Diabetes Drugs market in Mexico is the shift towards combination therapies. This involves combining different types of drugs to achieve better glycemic control and reduce the risk of side effects. Another trend is the growing popularity of GLP-1 receptor agonists, which are injectable drugs that help to control blood sugar levels.

Local special circumstances: Mexico has a large population of people with diabetes, which is driving demand for anti-diabetes drugs. Additionally, the country has a well-established healthcare system that provides access to these medications. However, there are also challenges in the market, such as the high cost of some drugs and the lack of awareness among some patients about the importance of managing their condition.

Underlying macroeconomic factors: Mexico has a growing economy and a large and expanding middle class, which is contributing to the growth of the Anti-Diabetes Drugs market. However, there are also challenges in the market, such as the high cost of some drugs and the lack of awareness among some patients about the importance of managing their condition. Additionally, the Mexican government has been implementing policies to promote the use of generic drugs, which could impact the market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.